Obinutuzumab (GA101) vs. rituximab significantly enhances cell death, antibody-dependent cytotoxicity and improves overall survival against CD20+ primary mediastinal B-cell lymphoma (PMBL) in a xenograft NOD-scid IL2Rgnull (NSG) mouse model: a potential targeted agent in the treatment of PMBL

Yaya Chu(New York Medical College), Mitchell S. Cairo(New York Medical College)

Oncotarget

August 11, 2020

10.18632/oncotarget.27691

Cited by 10

Related Papers

Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients

|Blood|2006|431

Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents

|Blood|2006|362

Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead

|Journal of Clinical Oncology|2015|288

Revised International Pediatric Non-Hodgkin Lymphoma Staging System

|Journal of Clinical Oncology|2015|238

Chemoimmunotherapy Reinduction With Epratuzumab in Children With Acute Lymphoblastic Leukemia in Marrow Relapse: A Children's Oncology Group Pilot Study

|Journal of Clinical Oncology|2008|210